Beulah Dadala is a CMC Consultant in Eliquent’s US Regulatory Affairs Practice group with a combination of academic and industrial research experience in sectors ranging from oncology to stem cell therapeutics and cell line development for mAb production.

Beulah Dadala joins Eliquent’s US Regulatory Affairs Practice as a CMC consultant. She comes from Johnson & Johnson’s Cell Line Development (CLD) group where she led multiple campaigns generating high titer cell lines for complex antibody therapeutics across multiple disease areas. CLD aside, she became an SME in lab automation and process development. In this role, she also represented her organization in interdepartmental CMC meetings to discuss our department’s impact on project timelines and milestones for different therapeutics.

Prior to working at J&J, Beulah gained experience working in the GMP team at Neurona Therapeutics and authored multiple documents per GDP guidelines in preparation for generating clinical material. Neurona Therapeutics is now in phase I/II clinical trials!

Beulah graduated with a bachelor’s degree in bioengineering and concentrated in cell and tissue engineering. During her time there, she completed internships at UCSF and Viriginia Tech, in addition to the University of Minnesota in a program funded by the NIH. Her research projects range from bioreactor design to stem cell differentiation research to cancer metastasis studies.